Quest Diagnostics Incorporated (NYSE:DGX) Receives Average Rating of “Hold” from Brokerages

Shares of Quest Diagnostics Incorporated (NYSE:DGXGet Free Report) have received an average recommendation of “Hold” from the ten analysts that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $146.91.

DGX has been the subject of several research analyst reports. Bank of America raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $140.00 to $160.00 in a research report on Tuesday, December 12th. TheStreet lowered shares of Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday, February 5th. JPMorgan Chase & Co. lifted their price target on shares of Quest Diagnostics from $148.00 to $149.00 and gave the company a “neutral” rating in a report on Friday, November 17th. Barclays began coverage on shares of Quest Diagnostics in a report on Wednesday, January 3rd. They issued an “equal weight” rating and a $145.00 target price on the stock. Finally, Jefferies Financial Group raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and boosted their target price for the stock from $140.00 to $155.00 in a report on Wednesday, February 7th.

Check Out Our Latest Stock Report on Quest Diagnostics

Institutional Investors Weigh In On Quest Diagnostics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Yousif Capital Management LLC increased its holdings in Quest Diagnostics by 5.3% in the 2nd quarter. Yousif Capital Management LLC now owns 26,926 shares of the medical research company’s stock worth $3,785,000 after acquiring an additional 1,359 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in Quest Diagnostics during the 3rd quarter worth $493,000. LPL Financial LLC boosted its stake in Quest Diagnostics by 4.4% during the 2nd quarter. LPL Financial LLC now owns 50,252 shares of the medical research company’s stock worth $7,063,000 after purchasing an additional 2,103 shares during the last quarter. Carson Advisory Inc. acquired a new stake in Quest Diagnostics during the 2nd quarter worth $185,000. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Quest Diagnostics by 1.3% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 16,439 shares of the medical research company’s stock worth $2,003,000 after purchasing an additional 218 shares during the last quarter. Hedge funds and other institutional investors own 87.76% of the company’s stock.

Quest Diagnostics Trading Up 2.6 %

Shares of DGX stock opened at $130.01 on Thursday. Quest Diagnostics has a 52-week low of $119.59 and a 52-week high of $148.91. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.20 and a current ratio of 1.31. The company has a 50-day simple moving average of $134.16 and a two-hundred day simple moving average of $131.42. The company has a market capitalization of $14.62 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 2.73 and a beta of 0.92.

Quest Diagnostics (NYSE:DGXGet Free Report) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.04. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The company had revenue of $2.29 billion for the quarter, compared to analysts’ expectations of $2.25 billion. During the same period in the prior year, the company posted $1.98 EPS. Quest Diagnostics’s revenue was down 1.9% compared to the same quarter last year. Research analysts anticipate that Quest Diagnostics will post 8.78 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 22nd. Stockholders of record on Monday, April 8th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 2.31%. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, April 5th. Quest Diagnostics’s payout ratio is 37.92%.

Quest Diagnostics Company Profile

(Get Free Report

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Stories

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.